Certain lymphomas and lung cancers have been reported to drive PD-L1 expression through the upregulation of the signal transducer and activator of transcription 3 (STAT3) and lymphoma kinase (ALK) signaling resistance (Pardoll, 2012). Here, STAT3 is linked to lung carcinoma.